Business
electroCore Extends VA Contract for Five Years
ROCKAWAY, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that electroCore has received a new Federal Supply Schedule (FSS) contract, with an effective date of June 15, 2025 and running through June 14, 2030. “Obtaining a follow-on contract in this macro environment is a tremendous vote of confidence by the Veterans Affairs (VA) FSS Service, demonstrating that gammaCore continues to be a co
About this update from Electrocore, Inc.
[{"type":"image","alt":"electroCore, Inc.","displaySize":"","headline":null,"caption":"electroCore, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":85,"url":"https://media.zenfs.com/en/globenewswire.com/7811b7d6996b3bdbba50262f0a2f8b72"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/uvgACRsMp7ZiIRhie6e7ow--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/7811b7d6996b3bdbba50262f0a2f8b72","width":300,"height":85}},"lazy":false},{"type":"text","content":"ROCKAWAY, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that electroCore has received a new Federal Supply Schedule (FSS) contract, with an effective date of June 15, 2025 and running through June 14, 2030.","length":315,"tagName":"p"},{"type":"text","content":"“Obtaining a follow-on contract in this macro environment is a tremendous vote of confidence by the Veterans Affairs (VA) FSS Service, demonstrating that gammaCore continues to be a cost effective therapeutic benefiting our veterans,” commented Dan Goldberger, Chief Executive Officer of electroCore. “VA Hospital revenue accelerated in February and March, after modest slowing in January 2025, reflecting continued demand for this drug-free method for addressing migraine headaches.”","length":489,"tagName":"p"},{"type":"text","content":"Mr. Goldberger continued, “On March 3, 2025, the VA terminated 585 non-mission critical or duplicative contracts following review by the new administration. This award of a new, five-year contract following such an audit further validates the value we provide the VA system and our veterans. We are greatly appreciative of the support we received during this two-year process from our FSS contract officer in ensuring our veterans have access to our non-opioid pain solution.” For more information regarding review and termination of VA contracts by the new administration, visit VA Press Release.","length":597,"tagName":"p"},{"type":"text","content":"The new contract has a five-year term and contains customary revisions, including prompt pay discounts and volume rebates on revenues greater than $10 million in a calendar year. We will continue to operate under the current contract until June 15, 2025, at which time the new ...